3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octane derivatives as smarca2 degrading protacs for the treatment of cancer

Abstract

The present disclosure provides compounds represented by Formula (A), or a pharmaceutically acceptable salt and / or stereoisomer thereof: Formula (A), wherein E is: Formula (I), Formula (II), or Formula (III); wherein Ra, Rb, Rc, R7, R8, R9, R10, X3, W, L, and E are as defined in the specification. Compounds represented by Formula (A) are SMARCA2 protein degraders and are thus useful for treating cancer and other diseases.